CNS drug development fails at 94% — not because the molecules don't work, but because subjective endpoints can't separate drug from placebo. VeraSolve compiles that uncertainty into enforceable, provenance-traced constraints: µLang, the NIRVANA inference engine, and a clinical framework proven across two disease verticals.